(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Federal judge upholds Hawaii's new climate change tax on cruise passengers - 2Minnesota jury says Johnson & Johnson owes $65.5 million to woman with cancer who used talcum powder
- 3The Delight of Perusing: Book Proposals for Each Class
- 4Medical team successfully delivers baby and removes massive tumor
- 5Vote In favor of Your Favored IT Administration
- Ethiopian earthquakes and volcanic eruptions: earth scientist explains the link
- Understanding Preschool Projects: An Extensive Aide
- Remote Headphones: Improve Your Sound Insight
- Scaling New Levels: Rock Climbing Spots On the planet
- Geminid meteors streak under green sky | Space photo of the day for Dec. 19, 2025
- CVS forecasts 2026 profit above estimates on strong performance
- Meet ‘NASA Mike,’ who’s done 105,000 handstands around the world
- EU states agree first step for Ukraine reparations fund
- What's inside Mexico's Popocatépetl? Scientists obtain first 3D images of the whole volcano
